Clinical Validation of a Highly Sensitive GC-MS Platform for Routine Urine Drug Screening and Real-Time Reporting of up to 212 Drugs

An important role of the clinical toxicology laboratory is to provide continuous diagnostic testing for patients with altered mental status and for other medical indications. To meet these needs, we have developed a new Gas Chromatography-Mass Spectrometry (GC-MS) platform that facilitates routine s...

Full description

Saved in:
Bibliographic Details
Main Authors: Hari Nair, Fred Woo, Andrew N. Hoofnagle, Geoffrey S. Baird
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:Journal of Toxicology
Online Access:http://dx.doi.org/10.1155/2013/329407
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849399290795917312
author Hari Nair
Fred Woo
Andrew N. Hoofnagle
Geoffrey S. Baird
author_facet Hari Nair
Fred Woo
Andrew N. Hoofnagle
Geoffrey S. Baird
author_sort Hari Nair
collection DOAJ
description An important role of the clinical toxicology laboratory is to provide continuous diagnostic testing for patients with altered mental status and for other medical indications. To meet these needs, we have developed a new Gas Chromatography-Mass Spectrometry (GC-MS) platform that facilitates routine screening and automated reporting of 212 drugs by laboratory technologists around the clock without the need to sign out by an on-site mass spectrometry-trained toxicologist. The platform uses a programmable temperature vaporizer (PTV) injector for large sample volume injection and the free software Automated Mass Spectral Deconvolution and Identification System (AMDIS) for data reduction and spectral matching that facilitates rapid library searching and analyte identification. Method comparison with 118 patient samples demonstrated that this platform and data searching algorithm independently provided improvements in sensitivity compared to an established GC-MS platform. Further examination of the role of the data processing software and the in-house databases used in the established versus the new platform demonstrated that the improved analytical sensitivity of the new platform was attributed to both the technical superiority of the new GC-MS instrumentation and the use of AMDIS in conjunction with the newly generated in-house library for data processing.
format Article
id doaj-art-9c15f0aecaf0459e9afd1f9f22794f23
institution Kabale University
issn 1687-8191
1687-8205
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series Journal of Toxicology
spelling doaj-art-9c15f0aecaf0459e9afd1f9f22794f232025-08-20T03:38:22ZengWileyJournal of Toxicology1687-81911687-82052013-01-01201310.1155/2013/329407329407Clinical Validation of a Highly Sensitive GC-MS Platform for Routine Urine Drug Screening and Real-Time Reporting of up to 212 DrugsHari Nair0Fred Woo1Andrew N. Hoofnagle2Geoffrey S. Baird3Department of Laboratory Medicine, University of Washington, P.O. Box 357110, 1959 NE Pacific Street, Seattle, WA 98185, USADepartment of Laboratory Medicine, University of Washington, P.O. Box 357110, 1959 NE Pacific Street, Seattle, WA 98185, USADepartment of Laboratory Medicine, University of Washington, P.O. Box 357110, 1959 NE Pacific Street, Seattle, WA 98185, USADepartment of Laboratory Medicine, University of Washington, P.O. Box 357110, 1959 NE Pacific Street, Seattle, WA 98185, USAAn important role of the clinical toxicology laboratory is to provide continuous diagnostic testing for patients with altered mental status and for other medical indications. To meet these needs, we have developed a new Gas Chromatography-Mass Spectrometry (GC-MS) platform that facilitates routine screening and automated reporting of 212 drugs by laboratory technologists around the clock without the need to sign out by an on-site mass spectrometry-trained toxicologist. The platform uses a programmable temperature vaporizer (PTV) injector for large sample volume injection and the free software Automated Mass Spectral Deconvolution and Identification System (AMDIS) for data reduction and spectral matching that facilitates rapid library searching and analyte identification. Method comparison with 118 patient samples demonstrated that this platform and data searching algorithm independently provided improvements in sensitivity compared to an established GC-MS platform. Further examination of the role of the data processing software and the in-house databases used in the established versus the new platform demonstrated that the improved analytical sensitivity of the new platform was attributed to both the technical superiority of the new GC-MS instrumentation and the use of AMDIS in conjunction with the newly generated in-house library for data processing.http://dx.doi.org/10.1155/2013/329407
spellingShingle Hari Nair
Fred Woo
Andrew N. Hoofnagle
Geoffrey S. Baird
Clinical Validation of a Highly Sensitive GC-MS Platform for Routine Urine Drug Screening and Real-Time Reporting of up to 212 Drugs
Journal of Toxicology
title Clinical Validation of a Highly Sensitive GC-MS Platform for Routine Urine Drug Screening and Real-Time Reporting of up to 212 Drugs
title_full Clinical Validation of a Highly Sensitive GC-MS Platform for Routine Urine Drug Screening and Real-Time Reporting of up to 212 Drugs
title_fullStr Clinical Validation of a Highly Sensitive GC-MS Platform for Routine Urine Drug Screening and Real-Time Reporting of up to 212 Drugs
title_full_unstemmed Clinical Validation of a Highly Sensitive GC-MS Platform for Routine Urine Drug Screening and Real-Time Reporting of up to 212 Drugs
title_short Clinical Validation of a Highly Sensitive GC-MS Platform for Routine Urine Drug Screening and Real-Time Reporting of up to 212 Drugs
title_sort clinical validation of a highly sensitive gc ms platform for routine urine drug screening and real time reporting of up to 212 drugs
url http://dx.doi.org/10.1155/2013/329407
work_keys_str_mv AT harinair clinicalvalidationofahighlysensitivegcmsplatformforroutineurinedrugscreeningandrealtimereportingofupto212drugs
AT fredwoo clinicalvalidationofahighlysensitivegcmsplatformforroutineurinedrugscreeningandrealtimereportingofupto212drugs
AT andrewnhoofnagle clinicalvalidationofahighlysensitivegcmsplatformforroutineurinedrugscreeningandrealtimereportingofupto212drugs
AT geoffreysbaird clinicalvalidationofahighlysensitivegcmsplatformforroutineurinedrugscreeningandrealtimereportingofupto212drugs